Ximelagatran

Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics[1][2].

Product Specifications

CAS Number

[192939-46-1]

Product Name Alternative

H 376/95

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Thrombin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ximelagatran.html

Purity

98.43

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C([C@@H]1CCN1C([C@@H](C2CCCCC2)NCC(OCC)=O)=O)NCC3=CC=C(C=C3)/C(N)=N/O

Molecular Formula

C24H35N5O5

Molecular Weight

473.57

Precautions

H302, H312, H332

References & Citations

[1]Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1 (10) :2119-30.|[2]Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore) . 2017 Oct;96 (40) :e8059.|[3]Francis CW, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349 (18) :1703-12.